Dr. Cohen on Challenges with Immunotherapy in Head and Neck Cancer

Ezra Cohen, MD
Published: Tuesday, Aug 08, 2017



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses challenges with immunotherapy in head and neck cancer.

It is difficult with a disease like head and neck cancer that has both a viral etiology and a tobacco-related etiology, says Cohen. There is not much different between response rates with the anti–PD-1s or the anti–PD-L1 agents for those 2 entities.

Additionally, Cohen says, head and neck squamous cell carcinoma is a rapidly progressing disease, and immunotherapy takes time to work—time that patients may not have.
 


Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses challenges with immunotherapy in head and neck cancer.

It is difficult with a disease like head and neck cancer that has both a viral etiology and a tobacco-related etiology, says Cohen. There is not much different between response rates with the anti–PD-1s or the anti–PD-L1 agents for those 2 entities.

Additionally, Cohen says, head and neck squamous cell carcinoma is a rapidly progressing disease, and immunotherapy takes time to work—time that patients may not have.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x